An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors

This study is testing a new experimental drug called ECI830 to see how well it works, alone or with other cancer treatments, for patients with specific types of advanced breast and lung cancers. The goal is to find the best dose to help fight cancer that has continued to grow after previous treatments.

This study is for adults with advanced hormone-positive/HER2-negative breast cancer or certain lung cancers that have not responded to standard therapies. You must have specific genetic markers in your cancer and meet certain health requirements regarding your heart, organ function, and previous treatment history.

Participants will receive the study drug ECI830, sometimes paired with other known medications like ribociclib or fulvestrant. You will have regular check-ups with the medical team to monitor your safety and see how your cancer responds to the treatment.

The study is currently recruiting patients at medical centers in Los Angeles, California; Fort Myers, Florida; and Boston, Massachusetts. Since it is an active study, you can speak with your doctor to see if one of these locations is right for you.